Medicare beneficiaries who rely on insulin will pay no more than $35 for a one-month supply of any covered insulin product in 2027, the same cap that has been in place since 2023. Federal statute requires every Part D plan and Medicare Advantage prescription drug plan to hold cost-sharing at or below that amount, with no deductible applied. The Contract Year 2027 Medicare Advantage and Part D Final Rule leaves the limit unchanged, meaning the protection carries forward without interruption into the next plan year.
How the $35 insulin cap shapes refill behavior through 2028
Before the Inflation Reduction Act established the $35 ceiling, many Medicare enrollees with diabetes faced monthly out-of-pocket insulin costs that could reach several hundred dollars, particularly during the Part D coverage gap. That financial pressure led some beneficiaries to ration doses or skip refills entirely. The cap removed the deductible for insulin and locked cost-sharing at a flat, predictable amount, according to Medicare guidance. With the limit now entering its fifth consecutive year, a reasonable expectation is that prescription refill rates among Medicare insulin users will continue to climb between 2025 and 2028, independent of the separate drug price negotiation provisions also created by the IRA. Stable, low cost-sharing reduces the single largest barrier to adherence: price at the pharmacy counter.
For patients, the behavioral effect of a simple, predictable copay can be as important as the dollar amount itself. Knowing that each insulin prescription will cost the same in January as in December, and that the deductible will not suddenly increase what is owed, makes it easier to budget and to schedule refills on time. Clinicians and care managers can also counsel patients with more confidence, since the out-of-pocket amount is standardized across plans for covered insulin products. Over multiple years, that predictability is likely to support better glycemic control and fewer avoidable hospitalizations related to skipped doses.
The cap may also influence which insulin formulations patients use. With the same maximum monthly cost applying to each covered product, some beneficiaries may be more willing to switch to analog insulins or other formulations recommended by their clinicians, rather than defaulting to older products solely because of price. However, the benefit still operates within each plan’s formulary rules, so prior authorization and tier placement can continue to shape which specific insulins are most accessible.
Statutory foundation for the monthly limit
The statutory foundation for the cap sits in Section 1395w-102 of the Social Security Act, which requires Part D sponsors to cover any covered insulin product with cost-sharing for a month’s supply that does not exceed the applicable copayment amount. That language applies to plan years beginning on or after January 1, 2025, building on earlier Inflation Reduction Act provisions that first took effect in 2023. Because the requirement is embedded in statute rather than annual rulemaking, plans cannot raise the cap without a change in law.
The law also interacts with broader Part D benefit changes that phase in over the next several years. As catastrophic cost-sharing is reduced and then eliminated for many drugs, the relative importance of the insulin-specific cap may shift. Still, for beneficiaries who use insulin but have limited spending on other medications, the $35 ceiling remains the most visible protection, ensuring that a single prescription cannot trigger a sudden spike in pharmacy bills.
Federal records confirming the $35 monthly ceiling
Multiple federal documents converge on the same figure. The Congressional Research Service, in its nonpartisan explainer on the Inflation Reduction Act’s health provisions, states that the law set a $35 cap on enrollee cost sharing for insulin under both Parts D and B, effective 2023. CMS reinforced that description in its own implementation materials, noting that cost-sharing for a month’s supply of each covered insulin is capped at $35. A separate CMS communication confirmed there is no deductible for these products for people with Medicare prescription drug coverage as of January 1, 2023.
The Contract Year 2027 final rule, described in a CMS fact sheet, carries these protections into the upcoming plan year without modification. The rule covers both traditional Part D standalone plans and Medicare Advantage plans that include drug benefits. For beneficiaries, the practical result is straightforward: regardless of which insulin product a doctor prescribes, the most a Medicare enrollee will generally owe at the pharmacy is $35 per month per covered product, with that limit applying even before any deductible would otherwise be met.
Gaps in the data on insulin cap enforcement and savings
Several questions remain open heading into 2027. CMS has not released plan-level compliance data showing how consistently Part D sponsors have adhered to the $35 limit or whether any plans have attempted to steer beneficiaries toward particular insulin products through utilization management. Public reporting has focused more on aggregate savings estimates than on audits or enforcement outcomes, leaving limited visibility into how disputes over coverage or copay calculations are resolved at the pharmacy counter.
There is also little nationally comparable information on how much individual Medicare beneficiaries have actually saved since the cap took effect. While anecdotal reports describe substantial reductions in monthly insulin bills, systematic data linking claims, plan design, and patient characteristics are not yet widely available. Without that detail, policymakers and researchers have fewer tools to assess whether the cap is closing disparities in access between different racial, ethnic, and income groups, or whether some communities continue to face higher rates of nonadherence.
Looking ahead to 2028, the durability of the $35 ceiling is clear in statute and regulation, but its full impact on health outcomes and health care spending is still emerging. More granular reporting on plan compliance, beneficiary savings, and refill behavior would help clarify how well the policy is functioning and where additional oversight or adjustments may be needed. For now, the core promise to Medicare insulin users remains unchanged: a predictable, affordable monthly cost that is designed to keep essential medications within reach.
Free for readers: The free Retirement Shield newsletter sends plain-English help keeping more of your money in retirement — the scams to dodge, the benefits you’re owed, and what’s changing with Social Security and Medicare, a couple times a week. Get the free newsletter.
